Through the 90-day period concluding December 12, 2025, Rapport Therapeutics's top three insider stakeholders include Chief Executive Officer Abraham Ceesay (609.72K shares), Chief Scientific Officer David Bredt (401.14K shares), Chief Operating Officer Cheryl Gault (171.93K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Rock Ventures V, L.P. Third | 8,104,451 | 10 Jun, 2024 | |
| Venture Partners Xii, Llc Arch | 3,728,738 | 10 Jun, 2024 | |
| Abraham Ceesay | Chief Executive Officer | 609,724 | 18 Nov, 2025 |
| David Bredt | Chief Scientific Officer | 401,142 | 18 Nov, 2025 |
| Cheryl Gault | Chief Operating Officer | 171,928 | 01 Dec, 2025 |
| Steven M Paul | 41,666 | 15 Sep, 2025 | |
| James Healy | 40,851 | 03 Jul, 2024 | |
| Reid M Huber | 20,400 | 15 Sep, 2025 | |
| Troy A. Ignelzi | Chief Financial Officer | 10,000 | 13 Mar, 2025 |
| Wendy B. Young | 9,500 | 11 Sep, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 26 Nov, 2025 | Cheryl Gault | Common Stock | A | 5,000 | $1.80 | 176,928 | D | M |
| 26 Nov, 2025 | Cheryl Gault | Common Stock | D | 5,000 | $30.10 | 171,928 | D | S |
| 17 Nov, 2025 | David Bredt | Common Stock | D | 3,156 | $24.84 | 406,486 | D | S |
| 17 Nov, 2025 | Abraham Ceesay | Common Stock | D | 2,777 | $24.92 | 576,802 | D | S |
| 17 Nov, 2025 | Abraham Ceesay | Common Stock | D | 3,056 | $25.43 | 573,746 | D | S |
| 17 Nov, 2025 | David Bredt | Common Stock | D | 5,344 | $25.39 | 401,142 | D | S |
| 17 Nov, 2025 | Abraham Ceesay | Common Stock | D | 2,242 | $24.91 | 38,819 | I | S |
| 17 Nov, 2025 | Abraham Ceesay | Common Stock | D | 2,841 | $25.44 | 35,978 | I | S |
| 15 Oct, 2025 | David Bredt | Common Stock | D | 7,418 | $25.73 | 410,724 | D | S |
| 15 Oct, 2025 | Abraham Ceesay | Common Stock | D | 4,647 | $25.72 | 580,765 | D | S |
| 15 Oct, 2025 | David Bredt | Common Stock | D | 1,082 | $26.16 | 409,642 | D | S |
| 15 Oct, 2025 | Abraham Ceesay | Common Stock | D | 1,186 | $26.14 | 579,579 | D | S |
| 15 Oct, 2025 | Abraham Ceesay | Common Stock | D | 4,328 | $25.75 | 41,816 | I | S |
| 15 Oct, 2025 | Abraham Ceesay | Common Stock | D | 755 | $26.17 | 41,061 | I | S |
| 17 Sep, 2025 | Abraham Ceesay | Common Stock | D | 39,435 | $26.30 | 586,812 | D | S |
| 17 Sep, 2025 | Abraham Ceesay | Common Stock | D | 1,400 | $26.87 | 585,412 | D | S |
| 17 Sep, 2025 | Abraham Ceesay | Common Stock | D | 34,885 | $26.30 | 46,844 | I | S |
| 17 Sep, 2025 | Abraham Ceesay | Common Stock | D | 700 | $27.04 | 46,144 | I | S |
| 15 Sep, 2025 | David Bredt | Common Stock | D | 5,098 | $23.88 | 421,544 | D | S |
| 15 Sep, 2025 | David Bredt | Common Stock | D | 3,402 | $24.66 | 418,142 | D | S |